MESA LABORATORIES INC (MLAB) Stock Fundamental Analysis
USA - NASDAQ:MLAB - US59064R1095 - Common Stock
69.17 USD
+4.02 (+6.17%)
69.17 USD
0 (0%)
Overall MLAB gets a fundamental rating of 5 out of 10. We evaluated MLAB against 55 industry peers in the Life Sciences Tools & Services industry. MLAB has a medium profitability rating, but doesn't score so well on its financial health evaluation. MLAB is not valued too expensively and it also shows a decent growth rate.
1. Profitability
1.1 Basic Checks
MLAB had positive earnings in the past year.
In the past year MLAB had a positive cash flow from operations.
The reported net income has been mixed in the past 5 years: MLAB reported negative net income in multiple years.
In the past 5 years MLAB always reported a positive cash flow from operatings.
1.2 Ratios
MLAB has a Return On Assets of -0.14%. This is in the better half of the industry: MLAB outperforms 61.82% of its industry peers.
MLAB has a better Return On Equity (-0.36%) than 63.64% of its industry peers.
MLAB has a better Return On Invested Capital (3.81%) than 65.45% of its industry peers.
The Average Return On Invested Capital over the past 3 years for MLAB is significantly below the industry average of 15.96%.
The 3 year average ROIC (1.90%) for MLAB is below the current ROIC(3.81%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.14% | ||
| ROE | -0.36% | ||
| ROIC | 3.81% |
ROA(3y)-19.07%
ROA(5y)-11.28%
ROE(3y)-58.62%
ROE(5y)-34.92%
ROIC(3y)1.9%
ROIC(5y)1.6%
1.3 Margins
The Operating Margin of MLAB (5.70%) is better than 61.82% of its industry peers.
In the last couple of years the Operating Margin of MLAB has remained more or less at the same level.
MLAB's Gross Margin of 62.12% is amongst the best of the industry. MLAB outperforms 81.82% of its industry peers.
In the last couple of years the Gross Margin of MLAB has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 5.7% | ||
| PM (TTM) | N/A | ||
| GM | 62.12% |
OM growth 3Y38.53%
OM growth 5Y0.45%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.88%
GM growth 5Y2.57%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), MLAB is destroying value.
MLAB has more shares outstanding than it did 1 year ago.
The number of shares outstanding for MLAB has been increased compared to 5 years ago.
The debt/assets ratio for MLAB has been reduced compared to a year ago.
2.2 Solvency
MLAB has an Altman-Z score of 0.74. This is a bad value and indicates that MLAB is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of 0.74, MLAB perfoms like the industry average, outperforming 41.82% of the companies in the same industry.
The Debt to FCF ratio of MLAB is 5.38, which is a neutral value as it means it would take MLAB, 5.38 years of fcf income to pay off all of its debts.
MLAB's Debt to FCF ratio of 5.38 is fine compared to the rest of the industry. MLAB outperforms 67.27% of its industry peers.
MLAB has a Debt/Equity ratio of 0.46. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of MLAB (0.46) is worse than 60.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.46 | ||
| Debt/FCF | 5.38 | ||
| Altman-Z | 0.74 |
ROIC/WACC0.38
WACC10%
2.3 Liquidity
MLAB has a Current Ratio of 0.66. This is a bad value and indicates that MLAB is not financially healthy enough and could expect problems in meeting its short term obligations.
The Current ratio of MLAB (0.66) is worse than 96.36% of its industry peers.
A Quick Ratio of 0.47 indicates that MLAB may have some problems paying its short term obligations.
MLAB's Quick ratio of 0.47 is on the low side compared to the rest of the industry. MLAB is outperformed by 94.55% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.66 | ||
| Quick Ratio | 0.47 |
3. Growth
3.1 Past
MLAB shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -98.30%.
The earnings per share for MLAB have been decreasing by -39.16% on average. This is quite bad
The Revenue has grown by 8.33% in the past year. This is quite good.
Measured over the past years, MLAB shows a quite strong growth in Revenue. The Revenue has been growing by 15.41% on average per year.
EPS 1Y (TTM)-98.3%
EPS 3Y-62.71%
EPS 5Y-39.16%
EPS Q2Q%1.19%
Revenue 1Y (TTM)8.33%
Revenue growth 3Y9.35%
Revenue growth 5Y15.41%
Sales Q2Q%2.36%
3.2 Future
MLAB is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 231.94% yearly.
Based on estimates for the next years, MLAB will show a small growth in Revenue. The Revenue will grow by 4.58% on average per year.
EPS Next Y2600.57%
EPS Next 2Y509.57%
EPS Next 3Y231.94%
EPS Next 5YN/A
Revenue Next Year3.51%
Revenue Next 2Y4.37%
Revenue Next 3Y4.58%
Revenue Next 5YN/A
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 864.63 indicates a quite expensive valuation of MLAB.
MLAB's Price/Earnings ratio is in line with the industry average.
MLAB's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 27.41.
A Price/Forward Earnings ratio of 26.59 indicates a quite expensive valuation of MLAB.
Compared to the rest of the industry, the Price/Forward Earnings ratio of MLAB indicates a somewhat cheap valuation: MLAB is cheaper than 72.73% of the companies listed in the same industry.
MLAB's Price/Forward Earnings ratio indicates a similar valuation than the S&P500 average which is at 22.88.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 864.63 | ||
| Fwd PE | 26.59 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, MLAB is valued cheaper than 89.09% of the companies in the same industry.
MLAB's Price/Free Cash Flow ratio is rather cheap when compared to the industry. MLAB is cheaper than 98.18% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 11.31 | ||
| EV/EBITDA | 13.34 |
4.3 Compensation for Growth
MLAB's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
MLAB has a very decent profitability rating, which may justify a higher PE ratio.
MLAB's earnings are expected to grow with 231.94% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.33
PEG (5Y)N/A
EPS Next 2Y509.57%
EPS Next 3Y231.94%
5. Dividend
5.1 Amount
MLAB has a Yearly Dividend Yield of 1.01%.
In the last 3 months the price of MLAB has falen by -27.81%. A price decline artificially increases the dividend yield. It may be a sign investors do not expect the dividend to last.
Compared to an average industry Dividend Yield of 1.09, MLAB pays a better dividend. On top of this MLAB pays more dividend than 98.18% of the companies listed in the same industry.
With a Dividend Yield of 1.01, MLAB pays less dividend than the S&P500 average, which is at 2.38.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.01% |
5.2 History
The dividend of MLAB decreases each year by -0.50%.
MLAB has paid a dividend for at least 10 years, which is a reliable track record.
MLAB has not decreased their dividend for at least 10 years, which is a reliable track record.
Dividend Growth(5Y)-0.5%
Div Incr Years0
Div Non Decr Years21
5.3 Sustainability
The earnings of MLAB are negative and hence is the payout ratio. MLAB will probably not be able to sustain this dividend level.
DP-560.97%
EPS Next 2Y509.57%
EPS Next 3Y231.94%
69.17
+4.02 (+6.17%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners95.72%
Inst Owner Change2.21%
Ins Owners5.12%
Ins Owner Change4.19%
Market Cap380.44M
Analysts80
Price Target90.27 (30.5%)
Short Float %7.66%
Short Ratio2.93
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.01% |
Yearly Dividend0.64
Dividend Growth(5Y)-0.5%
DP-560.97%
Div Incr Years0
Div Non Decr Years21
Ex-Date
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-63.49%
Min EPS beat(2)-217.83%
Max EPS beat(2)90.84%
EPS beat(4)1
Avg EPS beat(4)-71.19%
Min EPS beat(4)-217.83%
Max EPS beat(4)90.84%
EPS beat(8)4
Avg EPS beat(8)363.88%
EPS beat(12)5
Avg EPS beat(12)215.08%
EPS beat(16)7
Avg EPS beat(16)149.42%
Revenue beat(2)0
Avg Revenue beat(2)-2.31%
Min Revenue beat(2)-3.63%
Max Revenue beat(2)-0.98%
Revenue beat(4)1
Avg Revenue beat(4)-0.45%
Min Revenue beat(4)-3.63%
Max Revenue beat(4)4.83%
Revenue beat(8)3
Avg Revenue beat(8)-0.52%
Revenue beat(12)4
Avg Revenue beat(12)-1.1%
Revenue beat(16)6
Avg Revenue beat(16)0.34%
PT rev (1m)-26.25%
PT rev (3m)-31.04%
EPS NQ rev (1m)-42.86%
EPS NQ rev (3m)-88.97%
EPS NY rev (1m)5.7%
EPS NY rev (3m)-56.29%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.3%
Revenue NY rev (1m)-1.01%
Revenue NY rev (3m)-1.26%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 864.63 | ||
| Fwd PE | 26.59 | ||
| P/S | 1.57 | ||
| P/FCF | 11.31 | ||
| P/OCF | 9.94 | ||
| P/B | 2.21 | ||
| P/tB | N/A | ||
| EV/EBITDA | 13.34 |
EPS(TTM)0.08
EY0.12%
EPS(NY)2.6
Fwd EY3.76%
FCF(TTM)6.12
FCFY8.85%
OCF(TTM)6.96
OCFY10.06%
SpS44.06
BVpS31.36
TBVpS-20.54
PEG (NY)0.33
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.14% | ||
| ROE | -0.36% | ||
| ROCE | 4.83% | ||
| ROIC | 3.81% | ||
| ROICexc | 4.12% | ||
| ROICexgc | N/A | ||
| OM | 5.7% | ||
| PM (TTM) | N/A | ||
| GM | 62.12% | ||
| FCFM | 13.89% |
ROA(3y)-19.07%
ROA(5y)-11.28%
ROE(3y)-58.62%
ROE(5y)-34.92%
ROIC(3y)1.9%
ROIC(5y)1.6%
ROICexc(3y)2.1%
ROICexc(5y)2.03%
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)2.4%
ROCE(5y)2.02%
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3Y106.13%
ROICexc growth 5Y21.15%
OM growth 3Y38.53%
OM growth 5Y0.45%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.88%
GM growth 5Y2.57%
F-Score5
Asset Turnover0.56
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.46 | ||
| Debt/FCF | 5.38 | ||
| Debt/EBITDA | 2.05 | ||
| Cap/Depr | 18.45% | ||
| Cap/Sales | 1.91% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 98.53% | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.66 | ||
| Quick Ratio | 0.47 | ||
| Altman-Z | 0.74 |
F-Score5
WACC10%
ROIC/WACC0.38
Cap/Depr(3y)13.3%
Cap/Depr(5y)13.77%
Cap/Sales(3y)1.71%
Cap/Sales(5y)1.8%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-98.3%
EPS 3Y-62.71%
EPS 5Y-39.16%
EPS Q2Q%1.19%
EPS Next Y2600.57%
EPS Next 2Y509.57%
EPS Next 3Y231.94%
EPS Next 5YN/A
Revenue 1Y (TTM)8.33%
Revenue growth 3Y9.35%
Revenue growth 5Y15.41%
Sales Q2Q%2.36%
Revenue Next Year3.51%
Revenue Next 2Y4.37%
Revenue Next 3Y4.58%
Revenue Next 5YN/A
EBIT growth 1Y58.81%
EBIT growth 3Y51.48%
EBIT growth 5Y15.93%
EBIT Next Year183.68%
EBIT Next 3Y46.94%
EBIT Next 5YN/A
FCF growth 1Y-6.91%
FCF growth 3Y6.74%
FCF growth 5Y10.67%
OCF growth 1Y-6.04%
OCF growth 3Y6.07%
OCF growth 5Y11.64%